FINGOLIMOD HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Fingolimod Hydrochloride patents expire, and what generic alternatives are available?
Fingolimod Hydrochloride is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Ltd, Bionpharma, Chartwell Rx, Dr Reddys, Ezra Ventures, Glenmark Pharms Ltd, Hec Pharm Co Ltd, Hetero Labs Ltd V, Mylan, Prinston Inc, Sun Pharm, Teva Pharms Usa, and Zydus Pharms. and is included in eighteen NDAs.
The generic ingredient in FINGOLIMOD HYDROCHLORIDE is fingolimod hydrochloride. There are twenty-one drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fingolimod Hydrochloride
A generic version of FINGOLIMOD HYDROCHLORIDE was approved as fingolimod hydrochloride by BIOCON LTD on December 4th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FINGOLIMOD HYDROCHLORIDE?
- What are the global sales for FINGOLIMOD HYDROCHLORIDE?
- What is Average Wholesale Price for FINGOLIMOD HYDROCHLORIDE?
Summary for FINGOLIMOD HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 17 |
| NDAs: | 18 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 139 |
| Clinical Trials: | 75 |
| Patent Applications: | 384 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FINGOLIMOD HYDROCHLORIDE |
| DailyMed Link: | FINGOLIMOD HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for FINGOLIMOD HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tang-Du Hospital | Phase 1/Phase 2 |
| The Methodist Hospital Research Institute | Phase 2 |
| General Hospital of Shenyang Military Region | Phase 4 |
Pharmacology for FINGOLIMOD HYDROCHLORIDE
| Drug Class | Sphingosine 1-phosphate Receptor Modulator |
| Mechanism of Action | Sphingosine 1-Phosphate Receptor Modulators |
Medical Subject Heading (MeSH) Categories for FINGOLIMOD HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for FINGOLIMOD HYDROCHLORIDE
Paragraph IV (Patent) Challenges for FINGOLIMOD HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| GILENYA | Capsules | fingolimod hydrochloride | 0.25 mg | 022527 | 1 | 2018-07-19 |
| GILENYA | Capsules | fingolimod hydrochloride | 0.5 mg | 022527 | 19 | 2014-09-22 |
US Patents and Regulatory Information for FINGOLIMOD HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | FINGOLIMOD HYDROCHLORIDE | fingolimod hydrochloride | CAPSULE;ORAL | 207991-001 | Oct 28, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | FINGOLIMOD HYDROCHLORIDE | fingolimod hydrochloride | CAPSULE;ORAL | 207994-001 | Oct 14, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | FINGOLIMOD HYDROCHLORIDE | fingolimod hydrochloride | CAPSULE;ORAL | 207971-001 | Jun 29, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
